When Medicare reimburses a cataract surgery in 2026, the surgical facility collects about $1,255.73 and the surgeon who performs the operation collects about $462.94. The facility earns roughly 2.71 times what the physician earns for the same fifteen minutes of work. The surgeon trained for more than a decade. The building trained for nothing. That gap is the single most misread number in ophthalmology economics, and it explains why a practice and the surgical center attached to it are two completely different investments wearing the same coat. An investor who buys the practice and rents the facility from someone else has purchased the smaller half of the business and handed the larger half to a landlord.

Why Ophthalmology Surgical Fees Split the Way They Do

The professional fee compensates the surgeon's time and skill. The facility fee compensates the room, the staff, the equipment, the sterilization, the recovery bay, and the overhead of keeping a Medicare-certified surgical center open and staffed. Cataract surgery moved out of the hospital and into ambulatory surgical centers decades ago because it is high volume, low complication, and fast, which is exactly the profile that makes a facility fee profitable at scale. The 2026 ASC payment rate for the standard cataract procedure rose to roughly $1,255.73 while the physician professional fee for the same code fell about 11 percent to $462.94, according to the ASCRS analysis of the 2026 ASC final rule. The two fees answer to different formulas and they have been moving in opposite directions for years, which means the spread an investor can capture by owning the facility widens almost automatically over time.

A surgeon without an ownership stake in the facility captures roughly one third of the total Medicare economics of the procedure they perform. The other two thirds flow to whoever owns the room. In most private-equity-backed ophthalmology platforms, the entity that owns the room is the platform, and the surgeon is an employee who generates the professional fee and watches the facility fee leave the building. The platform understood the split. The surgeon, in many cases, signed the deal without realizing the better half of the economics was being assigned to a layer above them. That information gap is part of why the model spread as quickly as it did.

How Ophthalmology ASC Ownership Compounds Over Time

The facility fee is not a one-time advantage that an investor captures once and books. It is a stream that grows along three separate curves at the same time. United States cataract volume runs near four million procedures a year and is projected to reach roughly six million by 2030 as the population ages, according to industry volume estimates drawing on CDC National Center for Health Statistics data. That is the volume curve. Facility reimbursement rises most years with the Medicare market basket update, which is the price curve. Premium intraocular lens upgrades stack additional cash-pay revenue on top of the Medicare base, which is the margin curve. A single surgical center sits at the intersection of rising volume, rising price, and rising upgrade revenue, and a buyer who owns it captures all three at once.

The valuation math follows the cash flow. Ambulatory surgical centers run operating margins above 23 percent on average, and single-specialty ophthalmology surgical centers trade at meaningful multiples on their own, separate from the practice. ASC ownership has historically added one to three turns of EBITDA at the point of sale, according to surgical center valuation analysis from FOCUS and FTI Consulting. A buyer who owns the facility owns a stream that gets larger every year the demographic curve steepens, and an asset the market prices as its own line item rather than a rounding error on the practice. The largest surgical center operators have understood this for years and have steadily increased their ownership share of the facility market as a result.

What Permanent Capital Sees in the Ophthalmology Facility

A fund with a ten-year life has to sell the surgical center on someone else's schedule, often the year before the volume curve enters its steepest stretch. The fund captures a few years of the facility fee, packages the center for sale, and hands the next decade of compounding to whoever buys it. A permanent holder keeps the room and harvests the next thirty years of compounding facility fees, premium lens attach, and rising surgical volume. The asset and the time horizon finally match, which is the entire structural argument for owning a surgical specialty permanently rather than renting exposure to it through a fund.

This is the reason a serious capital allocator should read an ophthalmology platform's surgical center ownership before reading anything else on the income statement. The practice is the patient relationship and the referral base. The facility is the annuity. The number most outside investors miss is the one Medicare prints in plain sight every year, because it sits in a fee schedule rather than a pitch deck.

What the Ophthalmology Facility Math Looks Like in Practice

Consider a single surgical center handling a modest two thousand cataract cases a year, a volume a single busy ophthalmologist can generate. At the 2026 facility rate of roughly $1,255 per case, the Medicare facility revenue alone is about $2.5 million before a single premium lens upgrade or retina procedure is counted. The professional fees those same two thousand cases generate, at roughly $463 each, come to about $926,000. An owner who holds only the practice and rents the facility captures the smaller figure and watches the larger one accrue to a landlord. An owner who holds both captures roughly $3.4 million in combined Medicare revenue from the same two thousand procedures, and that figure grows with volume, with the annual market basket update, and with every percentage point of premium lens conversion layered on top.

Now extend the horizon. A private equity fund that acquires that center in year three of a ten-year fund has perhaps four or five years to harvest the facility fee before it must package the asset for sale. It captures a slice of a rising stream and sells the rest. A permanent holder captures the full arc, including the steepest part of the volume curve that arrives in the 2030s as the cataract wave crests. The same asset produces a fundamentally different return depending on whether the owner is forced to sell into the middle of its best decade or free to hold through it. That difference is not an operating improvement or a financial engineering trick. It is the simple arithmetic of time, applied to a recurring fee that compounds.

A skeptic might argue that surgical center ownership carries regulatory and operational complexity, which is fair. Certificate-of-need rules in some states, the cost of equipping and staffing a Medicare-certified center, and the safe-harbor requirements governing physician ownership of facilities are all real considerations that demand competent management and proper structure. None of them change the underlying economics. They are reasons to operate the facility well, not reasons to hand its larger share of the procedure economics to someone else. The building earns more than the surgeon, the building earns more every year, and the building can be owned permanently by a holder with no clock forcing a sale. An investor who understands that is reading a different business than the one private equity spent a decade selling to itself.

This article is for general educational purposes and is not legal or financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a practice owner thinking about succession or a physician exploring ownership, we're open to thoughtful conversations.

Contact info@verdira.com | 307-381-3734 | verdira.com